Literature DB >> 31585799

CARdiac Immunotherapy: T Cells Engineered to Treat the Fibrotic Heart.

Ronald J Vagnozzi1, Anne Katrine Z Johansen1, Jeffery D Molkentin2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31585799      PMCID： PMC6838878          DOI： 10.1016/j.ymthe.2019.09.021

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  24 in total

1.  Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction.

Authors:  Jochen Tillmanns; Daniel Hoffmann; Yasmin Habbaba; Jan D Schmitto; Daniel Sedding; Daniela Fraccarollo; Paolo Galuppo; Johann Bauersachs
Journal:  J Mol Cell Cardiol       Date:  2015-08-28       Impact factor: 5.000

Review 2.  Innate immunity and the failing heart: the cytokine hypothesis revisited.

Authors:  Douglas L Mann
Journal:  Circ Res       Date:  2015-03-27       Impact factor: 17.367

3.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

Authors:  P Garin-Chesa; L J Old; W J Rettig
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

Authors:  Theodoros Giavridis; Sjoukje J C van der Stegen; Justin Eyquem; Mohamad Hamieh; Alessandra Piersigilli; Michel Sadelain
Journal:  Nat Med       Date:  2018-05-28       Impact factor: 53.440

5.  Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.

Authors:  John Scholler; Troy L Brady; Gwendolyn Binder-Scholl; Wei-Ting Hwang; Gabriela Plesa; Kristen M Hege; Ashley N Vogel; Michael Kalos; James L Riley; Steven G Deeks; Ronald T Mitsuyasu; Wendy B Bernstein; Naomi E Aronson; Bruce L Levine; Frederic D Bushman; Carl H June
Journal:  Sci Transl Med       Date:  2012-05-02       Impact factor: 17.956

Review 6.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

7.  Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Authors:  Liang-Chuan S Wang; Albert Lo; John Scholler; Jing Sun; Rajrupa S Majumdar; Veena Kapoor; Michael Antzis; Cody E Cotner; Laura A Johnson; Amy C Durham; Charalambos C Solomides; Carl H June; Ellen Puré; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2013-11-12       Impact factor: 11.151

Review 8.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

9.  Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience.

Authors:  Danielle S Burstein; Shannon Maude; Stephen Grupp; Heather Griffis; Joseph Rossano; Kimberly Lin
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-14       Impact factor: 5.742

10.  Targeting cardiac fibrosis with engineered T cells.

Authors:  Haig Aghajanian; Toru Kimura; Joel G Rurik; Aidan S Hancock; Michael S Leibowitz; Li Li; John Scholler; James Monslow; Albert Lo; Wei Han; Tao Wang; Kenneth Bedi; Michael P Morley; Ricardo A Linares Saldana; Nikhita A Bolar; Kendra McDaid; Charles-Antoine Assenmacher; Cheryl L Smith; Dagmar Wirth; Carl H June; Kenneth B Margulies; Rajan Jain; Ellen Puré; Steven M Albelda; Jonathan A Epstein
Journal:  Nature       Date:  2019-09-11       Impact factor: 49.962
View more
  5 in total

Review 1.  Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections.

Authors:  Ekaterina Zmievskaya; Aygul Valiullina; Irina Ganeeva; Alexey Petukhov; Albert Rizvanov; Emil Bulatov
Journal:  Biomedicines       Date:  2021-01-09

Review 2.  Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer.

Authors:  Carlos Moreno; Christopher Haynie; Abigail Johnson; K Scott Weber
Journal:  Biomedicines       Date:  2022-06-24

Review 3.  A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis.

Authors:  Solveig A van der Vegt; Ying-Jie Wang; Liudmila Polonchuk; Ken Wang; Sarah L Waters; Ruth E Baker
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

Review 4.  Cardiac ECM: Its Epigenetic Regulation and Role in Heart Development and Repair.

Authors:  Rui Song; Lubo Zhang
Journal:  Int J Mol Sci       Date:  2020-11-15       Impact factor: 5.923

5.  Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04.

Authors:  Susan Notohamiprodjo; Stephan G Nekolla; Stephanie Robu; Alberto Villagran Asiares; Christian Kupatt; Tareq Ibrahim; Karl-Ludwig Laugwitz; Marcus R Makowski; Markus Schwaiger; Wolfgang A Weber; Zohreh Varasteh
Journal:  J Nucl Cardiol       Date:  2021-04-15       Impact factor: 3.872
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.